AI researcher ‘turns down $1bn pay offer from Mark Zuckerberg'
Mr Zuckerberg's Meta reportedly offered several researchers who work at Thinking Machines, a San Francisco-based AI start-up, packages worth hundreds of millions of dollars to join the social media giant.
One of those packages would have been worth as much as $1bn over several years, according to a report from Wired, while some researchers were also offered between $200m and $500m over a four-year period. Most deals included an award worth $50m to $100m in the first year.
So far, no staff at the start-up have taken up an offer from Meta. Last month, Thinking Machines raised $2bn at a $12bn valuation, despite having no product.
A spokesman for Meta disputed the claims, although confirmed it had made a 'handful' of offers to staff at Thinking Machines.
'We made offers only to a handful of people at Thinking Machines and while there was one sizeable offer, the details are off,' the spokesman said.
Thinking Machines was founded by 36-year-old Mira Murati, a former OpenAI executive who has become one of the powerful women in tech since launching the company.
AI arms race
The eye-watering pay offers come amid an AI arms race, with tech giants trying to tempt leading AI scientists and programmers to join their efforts over those of rivals.
Sam Altman, the chief executive of OpenAI which owns ChatGPT, previously claimed Meta had offered his staff deals worth as much as $100m.
Mr Zuckerberg has been personally leading a recruitment drive to attract leading scientists and developers to a new lab within Meta in a race against rivals to build highly powerful AI tools.
The Meta chief executive has reportedly been reaching out to dozens of targets with personalised WhatsApp messages and bumper pay deals.
Meta is spending tens of billions of dollars on AI data centres that will be used to help create more powerful machine-learning tools that Mr Zuckerberg has claimed could soon transform the economy and society.
He has also already recruited around 50 leading researchers and experts for a new 'superintelligence' lab within Meta, after growing frustrated at the lack of progress by his own engineers.
Earlier this year, Meta delayed a major update to its AI technology, dubbed Behemoth.
Mr Zuckerberg also engineered a $14.3bn deal to poach Alexandr Wang, the founder of AI business Scale AI, to lead his new team, acquiring a 49pc stake in the start-up in the process.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 minutes ago
- The Independent
Americans are cutting their spending amid economic uncertainty, reports show
Economic uncertainty is prompting Americans to significantly reduce spending six months into Donald Trump 's second term. Consumer spending growth has slowed considerably, with a marginal 0.1 percent increase in June following a decline in May. New tariffs introduced by Donald Trump, effective from August 1, are forecast to cost the average household $2,400 by 2025. The U.S. economy added only 73,000 jobs in July, a dismal report that reportedly led to the dismissal of the chief labor statistician. Widespread consumer anxiety is evident, with many concerned about rising costs for groceries and housing, leading to reduced purchases across various sectors.
Daily Mail
3 minutes ago
- Daily Mail
CNN expert pays Trump the ultimate compliment while discussing tariffs
CNN 's data expert Harry Enten called Donald Trump the most influential president of the 21st century. Enten - who often breaks down polling issues for the left-leaning network - said that Trump is 'remaking' America in a way George W. Bush, Barack Obama and Joe Biden didn't. He credits that to Trump's hardline policy to fix the southern border and even his controversial tariff policies. 'I can't think of a more influential president during this century, and it starts here with tariffs. He said he was going to raise tariffs, and despite the claims otherwise, he is in fact doing that,' Enten said. He noted that tariffs are now 'nine times as high as it was last year. The highest since the 90s.' Enten then pivoted to how Trump has influenced America via his immigration policies. 'The other big thing that Trump ran on was immigration. How about net migration in the United States? Get this, it's down. It's going to be down at least 60%. We may be dealing with, get this, negative net migration to the United States in 2025,' he said. He added that this would be the first time America had negative net migration in a half a century. 'So Donald Trump has always run on tariffs, and he's running a hawkish line on immigration,' he said. 'And on both of those issues we are seeing record high tariff rates for this century going all the way back, well back into the early part of the 20th century. And when it comes to immigration, net migration We are seeing record low levels way down from where we were during the Biden administration.' Trump's influence and popularity lines up with a recent exclusive Daily Mail/J.L. Partners poll, even as they give him failing grades for his handling of the Jeffrey Epstein files. Forty-nine percent of voters now approve of Trump's job performance as president, up one point from the tracking survey conducted earlier in July. But he remains underwater as 51 percent disapprove of Trump's job performance, down one point from earlier in the month. The margin of error in the survey of 1,007 registered voters is 3.1 percent. The poll numbers suggest Trump is surviving politically during a punishing news cycle consumed by the Epstein files and his administration's failure to disclose them as he promised during his presidential campaign. The president's job approval is up one percentage point from June and remains his highest rating since May. 'The news saga might have seemed terrible for Trump in the last few days, but it isn't having an impact on his approval rating,' James Johnson, JL Partners co-founder told the Daily Mail. 'In fact, we think it's going up, from 48 percent to 49 percent, making this his best approval rating since May. His ratings with the base is holding up too, unchanged on 91 percent with Republicans,' Johnson continued. But Trump's strong job approval ratings does not carry over to his handling of the Epstein files. Forty-two percent of voters disapprove of his handling of the issue while just 27 percent approve. A significant number of voters, 20 percent, did not appear to care about the case as they neither approved nor disapproved Trump's handling of the issue. In the Oval Office on Wednesday, Trump referred to the ongoing saga as a 'witch hunt' indicating he was tired of answering questions from the media about it. Despite the president's best efforts to put the issue behind him, few voters believe in the administration's assessment of the case. Only fifteen percent in the poll said they believed the Justice Department's memo released by Attorney General Pam Bondi concluding that Epstein committed suicide in prison and that the infamous pedofile did not have a 'client list' they could release. Forty-seven percent said they did not believe the administration's account of the Epstein case, and that they believed there was more secrets to uncover. Twenty-three percent said they believed the Trump administration memo, but that there was more to uncover in the case. Ninety percent of the Republican voter base continue to grant the president solid approval ratings, despite their misgivings about the Epstein files. The poll was conducted as Trump furiously contested a Wall Street Journal report that he had signed a letter to Epstein for his 50th birthday which concluded: 'Happy Birthday - and may every day be another wonderful secret,' and featured a hand-drawn image of a naked woman as well as his signature. Trump decried the news article as 'fake' and filed a $10 billion lawsuit against the company. 'They are judging Trump on other issues - such as the economy, the southern border, and how he is actually running the country. Their grumbles on the Epstein handling are not enough for them to turn on their man,' Johnson said. While the majority of Republicans, 52 percent, give Trump a passing grade on his handling of the Epstein files, just 13 percent of Independent voters feel the same way.
Reuters
3 minutes ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
